AI Analysis | Feedback

Here are 1-3 brief analogies for Immunome (IMNM):

• An early-stage Regeneron, but focused on discovering antibody drugs directly from the human immune system.
• A specialized antibody drug developer, akin to a nimble, early-stage Genentech, but focused on uncovering therapeutic antibodies from the natural immune responses of disease survivors.
• A biotech 'bioprospecting' for therapeutic antibodies, similar to the drug discovery efforts of major biotech firms like Amgen, but specifically by mining the human immune system.

AI Analysis | Feedback

• IMM-101: A clinical-stage therapeutic designed to treat autoimmune and inflammatory diseases by blocking specific co-stimulatory pathways.
• IMM-B005: A clinical-stage therapeutic aimed at treating B-cell mediated autoimmune diseases, such as lupus, by inhibiting B-cell activating factors.
• IMM-ONC-01: A clinical-stage therapeutic antibody targeting HER3 for the treatment of various cancers.

AI Analysis | Feedback

Immunome (symbol: IMNM) is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics. As such, it does not currently have approved commercial products on the market and does not sell directly to individuals or traditional commercial customers like hospitals or pharmacies.

Instead, Immunome generates revenue primarily through strategic collaborations, licensing agreements for its technology and pipeline, and government grants for its research and development initiatives. In this context, its "major customers" are other companies that partner with Immunome for its drug discovery capabilities.

One major strategic partner and a key "customer" in terms of licensing and collaboration for its technology platform is:

• AbbVie Inc. (NYSE: ABBV)

Immunome has a license and collaboration agreement with AbbVie for the development and commercialization of antibody-drug conjugates (ADCs) using Immunome's proprietary discovery engine.

Additionally, Immunome has received substantial funding through grants from government agencies, such as the Biomedical Advanced Research and Development Authority (BARDA) for specific research programs (e.g., against SARS-CoV-2). While these grants represent significant funding, BARDA is a government agency and not a commercial company customer in the traditional sense.

AI Analysis | Feedback

• Lonza Group AG (LHN.SW)
• JSR Corporation (4185.T)
• Wacker Chemie AG (WCH.DE)
• Catalent (CTLT)

AI Analysis | Feedback

Clay Siegall, Ph.D. President & Chief Executive Officer

Dr. Clay Siegall was appointed President and Chief Executive Officer of Immunome in October 2023. He previously served as CEO of Morphimmune, overseeing its merger with Immunome. Dr. Siegall co-founded Seagen (formerly Seattle Genetics) in 1998 and led it as CEO for nearly 25 years, where he was instrumental in establishing antibody-drug conjugates (ADCs) as a cornerstone of cancer therapy. Under his leadership, Seagen achieved FDA approvals for four cancer therapies and grew to over $2 billion in annual revenue. Seagen was acquired by Pfizer for $43 billion in 2023. Prior to founding Seagen, he held leadership positions at Bristol Myers Squibb and the National Cancer Institute.

Max Rosett Chief Financial Officer

Max Rosett joined Immunome in October 2023 at the close of the company's merger with Morphimmune and was promoted to Chief Financial Officer in May 2024, after serving as Interim CFO since January 2024. Before joining Immunome, he was Acting Chief Operating Officer at Morphimmune. Mr. Rosett previously served as a Principal and Director of Data Science at Research Bridge Partners, a life science investment firm. He also worked as a software engineer at Google and began his career at the Boston Consulting Group, where he advised pharmaceutical industry clients. Mr. Rosett has been instrumental in Immunome's merger with Morphimmune, strategic transactions, and financings totaling over $350 million.

Jack Higgins, Ph.D. Chief Scientific Officer

Dr. Jack Higgins is a biotechnology leader with over a decade of experience. He previously spent 11 years at Molecular Templates, Inc., rising to Chief Development Sciences Officer. At Molecular Templates, he led discovery and development efforts for multiple clinical candidates and co-invented the company's Engineered Toxin Body (ETB) platform. Dr. Higgins completed a fellowship in tumor immunology at the National Cancer Institute.

Kinney Horn Chief Business Officer

Kinney Horn has over twenty years of experience in life science finance, leadership, operations, and biopharmaceutical business development, with transactions exceeding $30 billion. Before joining Immunome, he was Chief Business Officer of Olema Oncology, where he contributed to an $85 million Series C financing and a $240 million IPO. He also served as an Entrepreneur in Residence at EcoR1 Capital. Mr. Horn spent 16 years at Genentech, where he identified preclinical and clinical stage opportunities, structured strategic alliances, and negotiated deals, and also worked with early-stage biotechnology companies invested in by GenenFUND, Genentech's private equity fund.

Bob Lechleider, M.D. Chief Medical Officer

Dr. Bob Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research. Prior to joining Immunome, he served as Chief Medical Officer at OncoResponse. Before that, Dr. Lechleider was Senior Vice President of clinical development for Seagen, where he was responsible for directing the development of early and late-stage portfolios, including the successful initial licensing of Padcev®. His biotech career began at MedImmune, followed by positions at Human Genome Sciences and Macrogenics.

AI Analysis | Feedback

The key risks to Immunome (IMNM) are:

1. Need for Additional Funding and Operating Losses: Immunome has a history of significant operating losses and is expected to continue incurring substantial losses as it advances its development programs. The company critically needs additional funds to progress its product candidates and platform, which may lead to difficulties in raising capital and potential dilution for shareholders through public offerings.
2. Clinical Development and Regulatory Approval Risks: As a clinical-stage biotechnology company, Immunome faces inherent risks that its product candidates may not successfully advance through clinical trials, receive the necessary regulatory approvals (such as from the FDA), or be successfully commercialized.
3. Competition: Immunome operates in a highly competitive oncology market and faces competition from other biotechnology and pharmaceutical companies developing similar therapies.

AI Analysis | Feedback

The clear emerging threat for Immunome is the rapid advancement and increasing sophistication of artificial intelligence (AI) and machine learning (ML) driven platforms for antibody discovery, design, and optimization. Companies leveraging AI/ML are demonstrating the ability to identify novel therapeutic antibody candidates, engineer improved antibody characteristics, and accelerate the preclinical development timeline with potentially greater efficiency and lower cost compared to traditional discovery methods, including Immunome's human memory B-cell platform. If these AI/ML platforms continue to mature and achieve significant clinical success, they could undermine the competitive advantage of Immunome's current discovery engine, making it more challenging to secure partnerships, attract talent, and bring differentiated products to market.

AI Analysis | Feedback

Immunome (NASDAQ: IMNM) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The addressable markets for their main product candidates are as follows:

Varegacestat (formerly AL102)

• Indication: Desmoid Tumors
• Market Size: The global desmoid tumors market was valued at approximately $2.68 billion in 2024 and is projected to reach $2.83 billion in 2025. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.94% to reach $3.79 billion by 2030. Another estimate places the global market at $2.5 billion in 2023, expanding to $5.2 billion by 2033, with a CAGR of 7.6% from 2024 to 2033.
• Region: Global. North America holds a significant share of this market, with an estimated size of $220 million in 2024, projected to grow to $550 million by 2034.

IM-1021 (ROR1-targeted Antibody-Drug Conjugate - ADC)

IM-1021 is in a Phase 1 clinical trial and is being investigated for indications including B-cell lymphoma and solid tumors such as triple-negative breast cancer (TNBC) and ovarian cancer.

• Indication: B-cell Lymphoma
• Market Size: The global B-cell lymphoma market size was approximately $5.08 billion in 2024 and is anticipated to increase to $5.44 billion in 2025, reaching roughly $10 billion by 2034 with a CAGR of 7.00% from 2025 to 2034.
• Region: Global. North America accounted for the largest share (39%) of the B-cell lymphoma market in 2024, with the U.S. market specifically valued at $1.39 billion in 2024, projected to reach $2.78 billion by 2034. The market across the top 7 major markets (US, EU4, UK, and Japan) was $5.0 billion in 2024 and is expected to reach $9.2 billion by 2035.

• Indication: Triple-Negative Breast Cancer (TNBC)
• Market Size: The global triple-negative breast cancer treatment market size was valued at around $490.53 million in 2024 and is expected to grow to approximately $741.61 million by 2034, with a CAGR of about 4.2% from 2025 to 2034. The metastatic TNBC market specifically is estimated at $1.65 billion in 2025 and is projected to reach $2.35 billion by 2032.
• Region: Global. North America held about 72% of the global triple-negative breast cancer treatment market revenue in 2022.

• Indication: Ovarian Cancer
• Market Size: The global ovarian cancer market size was valued at $1.35 billion in 2024 and is anticipated to grow from $1.81 billion in 2025 to $31.64 billion by 2033, at a CAGR of 23.8%. Another report estimates the global market at $3.06 billion in 2023, expected to reach $31.31 billion by 2034, with a CAGR of 23.53%.
• Region: Global. North America is anticipated to have the highest revenue share. The ovarian cancer market in the seven major markets (US, 5EU, Japan) was $3.3 billion in 2022.

IM-3050 (FAP-targeted radioligand therapy) and Preclinical ADCs (IM-1617, IM-1340, IM-1335)

Specific addressable market sizes for IM-3050 (FAP-targeted radioligand therapy) or the individual preclinical ADCs (IM-1617, IM-1340, IM-1335) are not readily available in the provided search results.

AI Analysis | Feedback

Immunome (IMNM) is a clinical-stage biotechnology company with several key programs anticipated to drive future revenue growth over the next two to three years. These drivers are primarily centered around advancing its oncology pipeline through clinical development and potential commercialization, as well as leveraging its proprietary technology.

1. Regulatory Approval and Commercialization of Varegacestat: Immunome's most advanced product candidate, varegacestat (formerly AL102), is currently in a Phase 3 clinical trial (RINGSIDE Part B) for the treatment of desmoid tumors. The company anticipates reporting topline data for this study in the second half of 2025. If positive, this data could lead to a New Drug Application (NDA) submission. A successful approval and subsequent commercial launch of varegacestat would represent a significant revenue driver, especially given its potential for orphan-drug exclusivity in an underserved market.
2. Advancement of IM-1021 through Clinical Development: IM-1021, a ROR1-targeted antibody-drug conjugate (ADC), received FDA clearance for its Investigational New Drug (IND) application in the fourth quarter of 2024, and the first patient was dosed in its Phase 1 clinical trial in February 2025. This trial is evaluating IM-1021 in patients with advanced B-cell lymphomas and solid tumors, with initial data expected in 2026. Successful progression through clinical stages and positive data could lead to significant future revenue through partnerships or eventual market entry.
3. Progression of IM-3050 into and through Clinical Trials: Immunome's FAP-targeted radioligand therapy, IM-3050, received IND clearance in April 2025. The company plans to initiate a Phase 1 clinical trial for IM-3050 in the second half of 2025 or early 2026. Advancement of this program through early clinical development would validate its potential and contribute to the long-term revenue growth profile of the company.
4. Development of Preclinical Antibody-Drug Conjugate (ADC) Pipeline: Immunome is actively advancing three preclinical ADCs (IM-1617, IM-1340, and IM-1335) that target solid tumors and incorporate its proprietary HC74 payload. These programs are moving towards IND submissions in 2026. The unique properties of the HC74 payload, which has demonstrated the ability to overcome multi-drug resistance, could differentiate these candidates and open avenues for future licensing agreements or commercialization.

AI Analysis | Feedback

Share Issuance

• In January 2025, Immunome completed an underwritten public offering of 22,258,064 shares of common stock at $7.75 per share, generating gross proceeds of $172.5 million.
• Immunome raised net proceeds of $215.4 million at $20 per share in a secondary offering in February 2024.
• The company received net proceeds of $44.9 million from two transactions under its at-the-market equity offering program as of September 30, 2025.

Inbound Investments

• Immunome and Morphimmune concurrently raised $125 million in a private placement deal during their reverse merger in June 2023.
• T. Rowe Price Investment Management Inc. held a $50.84 million stake in Immunome as of August 2025.
• Driehaus Capital Management LLC invested $4.11 million in Immunome in September 2025.

Outbound Investments

• Immunome acquired AL102 from Ayala Therapeutics in March 2024 for $20 million in cash and $30 million in Immunome common stock at closing, plus up to $37.5 million in development and commercial milestone payments.
• The company purchased a collection of antibody-related assets from Atreca for $12.5 million, which included a $5.5 million upfront payment and up to $7 million in clinical development milestones.
• In 2023, Immunome absorbed Morphimmune through a reverse subsidiary merger, which strategically expanded its oncology pipeline and technological base.

Capital Expenditures

• Research and development expenses were substantial, reaching $49.2 million for the third quarter of 2025 and $129.5 million for the full year 2024.
• The primary focus of these expenditures is advancing its pipeline of targeted cancer therapies, including varegacestat (Phase 3), IM-1021 (ROR1 ADC in Phase 1), IM-3050 (FAP-targeted radioligand), and other preclinical antibody-drug conjugates (ADCs).
• Immunome expects its current cash position to fund operations, primarily R&D, into 2027.